Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

"EC approves argenx’s efgartigimod alfa for CIDP treatment" was originally created and published by Pharmaceutical Technology ...

CIDP Treatment. Most people need treatment. And the sooner you begin it, the better the chance of a complete recovery. Sometimes symptoms go away for a long time but come back later.

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the ...

This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...

CIDP treatment evolves with novel approvals like Vyvgart Hytrulo and HYQVIA, offering patients new, less invasive and more convenient therapy options. As CIDP moves toward targeted therapies and ...

Physicians from Bochum have used a cancer treatment method to treat severe autoimmune diseases.

ADHERE enrolled 322 adult patients with CIDP, 130 of whom were based in Europe, who were off treatment (not on active treatment within the past six months or newly diagnosed) or being treated with ...

VYVGART is the first IgG Fc-antibody fragment targeting CIDP and marks the first CIDP treatment with a novel mechanism of action in more than 30 years, if approved. The treatment is designed for ...

Argenx (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the US, Japan, China, the Netherlands, and internationally.

VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than ...